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Core evidence place in therapy summary for prucalopride in chronic constipation

  **Outcome measure**                                                                                        **Evidence**   **Implications**
  ---------------------------------------------------------------------------------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------
  **Patient-oriented evidence**                                                                                             
  Statistically significant percentage of patients with increase of ≥1 spontaneous complete bowel movement   Clear          Improved symptom control and less need for laxatives
  Percentage of patients with ≥3 spontaneous complete bowel movements and relief of constipation             Substantial    Prucalopride can restore normal bowel function in a subgroup of difficult to treat patients
  Improvement of perceived severity of constipation and of constipation-related symptoms                     Clear          Improved symptom control
  Maintenance of clinical response                                                                           Moderate       Prucalopride may be used long term
  Significant improvement of disease-specific quality of life                                                Moderate       Prucalopride can be considered as first-line treatment in patients in whom laxatives fail
  Overall treatment satisfaction                                                                             Moderate       Prucalopride can be used as first-line treatment in patients in whom laxatives fail
  Reduced need for laxatives                                                                                 Limited        Additional laxatives may be required in patients with more severe symptoms
  Efficacy superior to laxatives                                                                             No evidence    No controlled comparative trials are available
  Efficacy in patients with associated pelvic floor dysfunction                                              Limited        Addition of prucalopride to current standard treatment may be useful
  Avoiding enemas or resectional surgery                                                                     No evidence    Controlled trials in the subgroup of patients with most severe signs and symptoms are awaited
  Absence of severe and cardiovascular adverse effects                                                       Moderate       A potential advance in the therapy of a population in need of a safe treatment providing adequate relief
  Mild adverse effect profile                                                                                Clear          Prucalopride can be used as first-line treatment and patients with a good response are likely to benefit in the long term
  **Disease-oriented evidence**                                                                                             
  Significant shortening of the time to first stool                                                          Clear          This finding may be in favor of pulse treatment, side effect profile permitting
  Significant increase in bowel movements with no straining                                                  Clear          Better symptom control and fewer laxative-induced side effects
  Significant increase in bowel movements with normal consistency                                            Clear          Better symptom control and fewer laxative-induced side effects
  Significant dose-dependent effect                                                                          Clear          Dose reduction for adverse events does not necessarily compromise relief of constipation
  Significant reduction in total colon transit time in patients with severe constipation                     Limited        Patients with more severe symptoms may require combination therapy with laxatives
  Significant reduction in oro-cecal transit time and right colonic emptying                                 Clear          Prucalopride may also be useful in patients with constipation and associated upper gastrointestinal motility disorders
  **Economic evidence**                                                                                                     
  Cost effectiveness compared with stimulant or other laxatives and pelvic floor retraining                  No evidence    Long-term pharmacoeconomic studies need to be designed

Scope, aims, and objectives
===========================

Although the pathogenesis of both normal and slow transit constipation is incompletely understood, there is plenty of evidence to develop serotonin-4 (5-HT~4~) receptor agonists in the treatment of chronic constipation as they accelerate transit, increase stool frequency, and improve stool consistency ([@b10-ce3_1p45]).

Prucalopride (Resolor^®^, Movetis) is a selective high affinity 5-HT~4~ receptor agonist that facilitates cholinergic and excitatory nonadrenergic, noncholinergic neurotransmission ([@b42-ce3_1p45]). The drug is orally active and acts via a systemic mechanism initiating high amplitude propagated contractions (HAPCs) in the colon ([@b23-ce3_1p45]). It enhances colonic propulsion and accelerates right colon emptying ([@b29-ce3_1p45]; [@b6-ce3_1p45]). Prucalopride also accelerates gastric emptying and small bowel transit ([@b6-ce3_1p45]). This review seeks to assess the scientific rationale for using prucalopride in chronic constipation and to discuss the current evidence for its role in the management of chronic constipation.

Methods
=======

English language literature searches were conducted on June 26, 2008 in the following databases, searching from the beginning of the database to date. The search terms used were "prucalopride", "prucalopride UEGW" or "prucalopride and constipation". The search strategy further included the limits "human, clinical trials, meta-analysis, randomized controlled trial", "clinical trial", or "meeting abstracts".

-   PubMed, <http://www.ncbi.nlm.nih.gov/entrez/queary.fcgi>, 1966 to date

-   EMBASE, <http://www.datastarweb.com>

-   National Institute for Health and Clinical Excellence (NICE), <http://www.nice.org.uk>

-   York University Centre for Reviews and Dissemination databases, <http://www.crd.york.ac.uk/crdweb/>

-   Google, [www.google.be](www.google.be)

Following removal of duplicates, reviews of drug class, treatment options, mechanistic studies in healthy volunteers, and pharmacokinetic studies, a total of six full papers and 11 abstracts were included in the evidence base. A summary of the literature search is presented in [Table 1](#t1-ce3_1p45){ref-type="table"}.

Disease overview
================

Constipation is a frequent gastrointestinal motility disorder with a prevalence ranging from 3% to 28% ([@b27-ce3_1p45]; [@b64-ce3_1p45]; [@b35-ce3_1p45]), and affecting mainly women ([@b37-ce3_1p45]). In daily practice constipation is defined on the basis of a combination of symptoms including \<2 bowel movements per week, hard stools, straining, false urge, and the feeling of incomplete emptying. The symptom constellation and underlying pathophysiologic mechanisms may vary considerably among patients ([@b44-ce3_1p45]). Chronic constipation negatively affects health-related quality of life and overall wellbeing, and generates high direct and indirect costs ([@b62-ce3_1p45]; [@b58-ce3_1p45]; [@b46-ce3_1p45]). It interferes with many aspects of patients' lives, including normal work, and is associated with psychologic morbidity ([@b19-ce3_1p45]; [@b21-ce3_1p45]; [@b43-ce3_1p45]). In most patients with chronic constipation no obvious dietary or structural causes for their symptoms can be demonstrated.

Chronic idiopathic constipation includes normal transit constipation, slow transit constipation, and rectal emptying disturbances with a significant overlap among the subgroups ([@b68-ce3_1p45]; [@b47-ce3_1p45]; [@b45-ce3_1p45]). They generate symptoms that are nonspecific.

Patients with normal transit constipation report constipation and associated symptoms of abdominal pain, bloating, or straining in the presence of uncoordinated contractions in the left colon with stool traversing the colon at a normal rate. They often fulfil the criteria of irritable bowel syndrome (IBS) ([@b18-ce3_1p45]). Patients with slow transit constipation have more severe complaints in the presence of delayed transit through the transverse colon that is accompanied by motility disturbances such as reduced HAPCs and the absence of early postprandial contractions ([@b2-ce3_1p45]; [@b3-ce3_1p45]). The etiology of these motility abnormalities is unclear. Occasionally, patients with more severe constipation also have a generalized gastrointestinal motility disorder ([@b66-ce3_1p45]). Rarely, slow transit constipation is associated with colonic inertia not responding to stimulant laxatives ([@b56-ce3_1p45]).

Rectal emptying disturbances, including rectoanal dyssynergia and pelvic floor dysfunction, are characterized by excessive straining, feeling of incomplete evacuation, to application of perineal pressure to assist evacuation or digital evacuation of even soft stools ([@b44-ce3_1p45]).

Role of the neurotransmitter serotonin in the regulation of gut function and constipation
-----------------------------------------------------------------------------------------

Serotonin or 5-hydroxytryptamine (5-HT) is a neurotransmitter that plays an important role in a broad range of functions in the gut. Serotonin exerts its effect in the body through a series of receptor subtypes of which the 5-HT~3~ and 5-HT~4~ receptor subtypes are best known in gastrointestinal physiology and physiopathology ([@b32-ce3_1p45]).

Binding of serotonin to 5-HT~4~ receptors stimulates peristalsis, modulates fluid content of the colonic content, and decreases visceral hypersensitivity ([@b18-ce3_1p45]; [@b22-ce3_1p45]). Patients with slow transit constipation have reduced numbers and function of colonic enterochromografine cells with decreased serotonin activity ([@b28-ce3_1p45]). It is postulated that this reduced serotonin activity may be associated with the motor and secretory abnormalities described in patients with slow transit constipation. These data make the 5-HT~4~ receptor an attractive mechanistic target for agents that may be useful in the treatment of constipation ([@b10-ce3_1p45]; [@b33-ce3_1p45]).

Current therapy options
=======================

A variety of treatment options have been proposed for patients with chronic constipation, including nonpharmacologic and pharmacologic interventions. However, data on the effectiveness of conservative nonpharmacologic strategies supported by clinical trials are limited ([@b36-ce3_1p45]). There is no evidence that increased exercise, fluid intake, and bowel habit training provide relief of all symptoms in patients with chronic constipation ([@b52-ce3_1p45]). Another conservative nonpharmacologic treatment option, biofeedback retraining of the pelvic floor, has been proposed in well-selected patients with rectoanal dyssynergia. There are now four randomized controlled trials (RCTs) which demonstrate that biofeedback is effective in a subgroup of patients with chronic constipation and the treatment of choice for dyssynergic defecation ([@b13-ce3_1p45], [@b14-ce3_1p45]; [@b34-ce3_1p45]; [@b59-ce3_1p45]). Meta analysis of studies involving biofeedback compared with other treatments suggested that biofeedback conferred a six-fold increase in the odds of treatment success ([@b40-ce3_1p45]). However, additional well-designed studies are also needed that take into account quality of life and psychologic morbidity.

Resectional surgery (subtotal colectomy with ileorectal anastomosis) carries the risk of incapacitating adverse effects and can only be considered in well-selected patients with slow transit constipation associated with colonic inertia not responding to stimulant laxatives and enemas ([@b15-ce3_1p45]; [@b54-ce3_1p45]).

Orally and rectally administered laxatives adapted to the individual patient are by far the most popular pharmacologic options for patients with chronic constipation. There is good evidence to support the use of osmotic laxatives, more particularly polyethylene glycol (PEG) in patients with chronic constipation. In contrast, there is a paucity of quality data for stimulant laxatives and glycerol ([@b57-ce3_1p45]) and head-to-head comparison to PEG is not available. But although the benefit of stimulant laxatives has not been supported by comprehensive clinical investigations, clinical experience indicates that laxatives such as bisacodyl, senna, and glycerol, tailored to the individual patient, are generally effective. As a rule, stimulant laxatives are effective in patients with slow transit constipation ([@b52-ce3_1p45]). A significant proportion of patients with chronic constipation are dependent on laxatives to achieve satisfactory bowel functions.

Osmotic laxatives such as nonabsorbed sugars, saline laxatives, and PEG increase intestinal water secretion. They may be used if fibre therapy fails. PEG was found to be more effective than lactulose ([@b57-ce3_1p45]). The evidence supporting the efficacy of lactulose is only moderate.

The short-term efficacy, tolerance, and safety of the class of osmotic laxatives are best documented for PEG-based laxatives, which have been shown to increase stool frequency and improve stool consistency ([@b24-ce3_1p45]; [@b12-ce3_1p45]). Obvious limitations of PEG-based laxatives are that only a subgroup of patients with mild chronic constipation respond, lack of effectiveness in providing adequate relief of all symptoms, and that they cause bloating, flatulence, and abdominal cramping eventually necessitating discontinuation of the laxative. There is now convincing evidence to support the efficacy and safety of PEG in the long term (6 months) in adult patients, including elderly patients with chronic constipation ([@b17-ce3_1p45]; [@b26-ce3_1p45]).

Stimulant laxatives, both the diphenylmethane and anthraquinone derivates, can be used on a regular basis when osmotic laxatives fail, but their long-term use may be limited by adverse effects, such as severe cramps, eventually necessitating discontinuation of the treatment ([@b60-ce3_1p45]). Tolerance to stimulant laxatives is rare and occurs mainly in the patients with more severe slow transit constipation. In contrast, the need to increase the dose over time is frequently observed ([@b4-ce3_1p45]). There are, however, no convincing data from pathology studies, performed by using adequate techniques, to support the belief that anthraquinone-containing laxatives may induce damage to the colon and its nerve plexuses ([@b52-ce3_1p45]).

Unmet needs
===========

The treatment of patients with normal or delayed colonic transit or outlet obstruction to defecation is nowadays far from always successful. This is particularly the case in the group of patients with more severe slow transit constipation and in patients with neurologic disorders such as Parkinson's disease, multiple sclerosis, and paraplegia. The main effect of laxatives is limited to emptying of the colon. Laxatives rarely provide adequate relief of all the complaints of the patient and frequently induce nausea, bloating, flatulence, distension, abdominal discomfort, and cramping abdominal pain ([@b52-ce3_1p45]; [@b26-ce3_1p45]).

Therefore, there is an urgent need for more effective, better tolerated, and safe treatments that normalize bowel function ([@b25-ce3_1p45]). In patients with impaired colonic propulsive motor activity, a gastrointestinal prokinetic may be a better therapeutic approach ([@b10-ce3_1p45]). Also, in patients with other types of chronic constipation, including those associated with dyssynergic defecation and pelvic floor dysfunction, it is reasonable to expect that the addition of a promotility agent to current standard treatment options may be useful. Patients with dyssynergic defecation may benefit from biofeedback, which produces greater reductions in symptoms, and the use of enemas and suppositories rather than continuous PEG. In most cases however, some form of laxative treatment will be required, particularly in patients with pelvic floor dyssynergia and slow transit constipation ([@b13-ce3_1p45]; [@b14-ce3_1p45]). The observation that abnormal serotonin signalling and reuptake appears to play a central role in the symptoms of a subset of patients with chronic constipation provides a rationale for the use of targeted serotonergic agents for the treatment of chronic constipation ([@b10-ce3_1p45]; [@b20-ce3_1p45]). Tegaserod, a selective partial 5-HT~4~ agonist, and to a much lesser extent cisapride, a first-generation promotility agent, were shown to reduce the need for laxatives and provide relief from multiple symptoms of constipation. However, concern about safety due to cardiotoxicity resulted in withdrawal of both promotility agents after they were approved by the FDA ([@b45-ce3_1p45]; [@b1-ce3_1p45]; [@b38-ce3_1p45]; [@b51-ce3_1p45]; [@b65-ce3_1p45]).

Clinical evidence for the use of prucalopride in chronic constipation
=====================================================================

Efficacy
--------

### Phase II trials

An initial phase II trial comparing prucalopride with placebo dates back to 1994 ([@b16-ce3_1p45]). This pilot study, which included mainly female patients with longstanding chronic constipation not responding adequately to laxatives and referred to a single tertiary referral center in Belgium, yielded promising results. Fifty-three patients were randomized in this placebo-controlled, double-blind trial. It was demonstrated that prucalopride 4 mg once daily for 4 weeks was significantly more effective than placebo in reducing time to first stool (*P*=0.071), softening stools (*P*=0.036), and decreasing straining (*P*=0.037). Prucalopride also had a positive effect on stool frequency, feeling of complete evacuation, and total gut transit time, but the differences were not statistically significant compared with placebo. Mean spontaneous stool frequency increased by 2.34 stools per week after prucalopride and by 1.48 stools per week after placebo, suggesting a strong placebo effect. The mean weekly frequency of laxative intake compared with the run-in period was reduced by 0.73±0.4 (mean± standard error of the mean) in the prucalopride group and by 0.59±0.24 in the placebo group. The difference, however, was not significant. Relief of constipation was experienced by a greater proportion of patients in the prucalopride group (37%) than in the placebo group (19.2%), and again, although clinically meaningful, the difference was statistically not significant. Dose reduction for excessive gastrointestinal response did not significantly influence stool frequency, stool consistency, degree of straining, or patients' overall relief of constipation. Total gut transit time showed a decrease of 10.39 hours with prucalopride compared with an increase of 7.45 hours with placebo. However, intergroup difference was not statistically significant, possibly because the mean total gut transit time during run-in was longer in the prucalopride group compared with placebo.

This initial experience with prucalopride treatment for severe chronic constipation supported further phase II investigations of prucalopride regimens in different forms of chronic constipation. The efficacy was further confirmed in six other phase II trials involving patients with chronic idiopathic constipation and one pilot phase II dose-escalation study in patients with constipation due to spinal cord injury.

[@b30-ce3_1p45] reported on 74 women with chronic constipation stratified into slow and normal transit groups. Each group was randomized to receive 1 mg prucalopride or placebo once daily for 4 weeks. In this single centre, double-blind, placebo-controlled trial conducted in the UK, prucalopride, not placebo, not only increased spontaneous stool frequency (*P*=0.008) and reduced time to first stool (*P*\<0.001), it also significantly improved disease-specific quality of life. Furthermore, prucalopride significantly reduced oro-cecal transit time and increased rectal sensitivity to distension compared with placebo. Prucalopride also reduced the mean number of retained radioopaque markers in the colon compared with placebo, but only in the subgroup with slow transit (*P*=0.069).

A subsequent phase II dose-finding study was conducted by [@b61-ce3_1p45] in the Netherlands, evaluating the effect of prucalopride in a short-term, double-blind, placebo-controlled, crossover study. Twenty-eight patients were randomized to receive prucalopride 1 or 2 mg once daily or placebo. Compared with placebo, prucalopride 1 mg significantly increased the mean number of complete spontaneous stools and all bowel movements per week. It also significantly decreased the percentage of bowel movements with hard stools and straining, and enhanced the urge to defecate. Significant changes in stool frequency, stool consistency, and need to strain were not seen with the 2 mg regimen. This may be explained by a relatively high frequency of bowel movements in this group of patients during placebo treatment. The effect of both 1 and 2 mg prucalopride on mean total colonic transit time was not different from the effect of placebo.

Another phase II dose-finding RCT including 251 patients conducted by [@b53-ce3_1p45] in the Netherlands, confirmed a clear dose-dependent increase (*P*=0.026) in the number of responders. Patients with chronic constipation (defined as having ≥2 of the following for ≥6 months: ≤2 spontaneous bowel movements per week, for ≥25% of the time, and/or hard stools, and/or straining, and/or a sense of incomplete evacuation) were randomized to prucalopride 0.5, 1, or 2 mg twice daily and treated for a 12-week period. Prucalopride 1 and 2 mg twice daily, but not 0.5 mg, significantly increased stool frequency (*P*\<0.01) and significantly decreased severity of constipation (*P*\<0.02). Clinical improvement with the higher doses correlated with a shorter transit time, with a significant time difference in the descending colon (*P*\<0.05), and the effect was maintained after 12 weeks. Time to the first spontaneous stool also significantly decreased with a median time of 22.4 hours for placebo versus 3 hours for the group taking prucalopride 2 mg twice daily.

Similar results were observed by [@b31-ce3_1p45] in a short-term, multicenter, phase II dose-finding study including 172 patients with chronic constipation also defined according to the Thompson criteria. Prucalopride 0.5, 1, or 2 mg administered once daily proportionally increased stool frequency (*P*\<0.05) and decreased the time to the first stool (*P*\<0.001). For patient self-assessment of bowel habit, therapeutic efficacy after 4 weeks of treatment with prucalopride 0.5--2 mg was apparent compared with placebo (*P*\<0.05). Prucalopride also significantly decreased total gut transit time from 49 to 39 hours at 1 mg and from 63 to 54 hours at 2 mg versus placebo.

These encouraging results were largely confirmed by a further phase II dose-finding study (n=234) with once daily doses of prucalopride 0.5--4 mg in the US ([@b48-ce3_1p45]). After 4 weeks there was a dose-dependent increase in the frequency of spontaneous complete bowel movements and in the percentage of responders defined as having ≥3 bowel movements per week: 32% with 2 mg (*P*\<0.05) and 54% with 4 mg (*P*\<0.001) versus 13% with placebo. There was also a significant beneficial dose-dependent effect on frequency of straining and stool consistency.

Subsequently, [@b39-ce3_1p45] performed a phase II multicenter, double-blind, placebo-controlled, dose-finding study in 303 elderly patients (age 65 years and over) with chronic constipation, defined as ≤2 spontaneous complete bowel movements per week. Patients were randomized to prucalopride 1, 2, or 4 mg once daily, or placebo for 4 weeks. They demonstrated that prucalopride increased the proportion of patients with ≥3 spontaneous complete bowel movements and improved constipated-related symptoms versus placebo, but the differences were not statistically significant. There was a significant increase in the proportion of patients with an increase of ≥1 complete bowel movement per week and an increase in the average change in the number of complete bowel movements with prucalopride.

Prucalopride in a dose of 1 or 2 mg appeared also to have definitive activity in patients with constipation due to spinal cord injury. [@b41-ce3_1p45] described their experience with 23 patients in a double-blind, placebo-controlled, pilot, phase II dose-escalation study of 4 weeks' duration. Compared with runin, the main measures of constipation severity decreased with prucalopride 1 and 2 mg. There was also an increase in average weekly frequency of all bowel movements over 4 weeks within the 2 mg group. The observed patient-reported improved bowel habit was accompanied by a significant reduction in median colon transit time by 38.5 hours \[95% confidence interval (CI): −80, −5\] within the 2 mg group.

[@b50-ce3_1p45] performed a phase II, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in 180 patients with constipation secondary to chronic daily opioid use. Prucalopride treatment improved bowel function and there was a trend toward improved quality of life. Prucalopride was also safe and well tolerated in these patients.

### Phase III trials

Two large, placebo-controlled, multicenter phase III trials to assess the therapeutic potential of prucalopride in severe chronic constipation confirm prucalopride's effectiveness and safety ([@b63-ce3_1p45]; [@b9-ce3_1p45]).

In the European multicenter, parallel-group, randomized, double-blind trial, efficacy was analyzed for 713 patients (90.8% female). Patients with \<2 spontaneous complete bowel movements per week with straining, or a sensation of incomplete evacuation, or with hard stools received oral doses of prucalopride 2 or 4 mg once daily or placebo for 12 weeks. Results were similar with both doses, which were significantly different from placebo (*P*≤0.01) at the primary endpoint; the percentage of patients with ≥3 spontaneous complete bowel movements per week averaged over 4 and 12 weeks were 10.4% and 9.6% for placebo, 23.7% and 19.5% for prucalopride 2 mg, and 26.6% and 23.6% for prucalopride 4 mg, respectively.

Furthermore, the percentage of patients with an increase of 1 or more spontaneous complete bowel movements per week, percentage of bowel movements with normal consistency, percentage of bowel movements with no straining, perceived severity of constipation, and overall score from a validated questionnaire measuring symptoms of constipation, were significantly improved with 2 and 4 mg prucalopride versus placebo averaged over 4 and 12 weeks.

Another placebo-controlled, randomized, parallel-group, phase III, 12-week trial conducted at 38 centers in the US with similar primary and secondary endpoints also showed significant effects ([@b9-ce3_1p45]). Efficacy was analyzed in 620 patients (87.9% female) with ≤2 spontaneous complete bowel movements per week. The responses to 2 and 4 mg doses were similar: 30.9% of those receiving 2 mg once per day of prucalopride and 28.4% of those receiving 4 mg once per day had ≥3 spontaneous complete bowel movements, compared with 12.0% in the placebo group (*P*\<0.001). Furthermore, over 12 weeks 47.3% of the patients receiving prucalopride 2 mg once per day and 46.6% of those receiving 4 mg once per day had an increase in the number of spontaneous, complete bowel movements of ≥1 per week, on average, compared with 25.8% in the placebo group (*P*\<0.001).

In addition, the use of prucalopride 2 or 4 mg, as compared with placebo, significantly reduced the use of bisacodyl tablets taken per week (*P*\<0.001). The median time to the first spontaneous, complete bowel movement was also significantly shorter after prucalopride compared with placebo. Furthermore, the percentage of patients quite satisfied or extremely satisfied with treatment efficacy during the 12-week period among the prucalopride 2 and 4 mg dose groups was significantly higher than among the placebo group (33.3% and 37.7%, respectively versus 17%, *P*\<0.001).

[@b67-ce3_1p45] performed an open label, phase III, multicenter, long-term follow-up study in patients with chronic constipation. Patients had received treatment with prucalopride 2 or 4 mg for 4 or 12 weeks in a double-blind placebo-controlled study, and were allowed to continue treatment for 24 months. Prucalopride was safe and well tolerated in the long term, and patient satisfaction with bowel function was maintained during the entire treatment period ([@b67-ce3_1p45]).

### Mechanistic studies

Prucalopride is known to stimulate gastrointestinal enterokinetic activity in animals in both *in-vitro* and *in-vivo* studies ([@b7-ce3_1p45],[@b8-ce3_1p45]). It has also enterokinetic effects in healthy volunteers ([@b29-ce3_1p45]; [@b5-ce3_1p45]; [@b55-ce3_1p45]). This dose-dependent effect, characterized by a significant increase in stool frequency and decrease in stool consistency with a higher percentage of loose/watery stools, is accompanied by a significant shortening of mean colonic transit time and proximal colonic emptying with prucalopride in doses ranging from 0.5--4 mg once daily ([@b5-ce3_1p45]; [@b55-ce3_1p45]). An effect of prucalopride in doses of up to 4 mg on gastric emptying or small bowel transit could not be demonstrated in healthy volunteers ([@b5-ce3_1p45]). In contrast, a physiologic study including 40 patients with chronic functional constipation and no evidence of a rectal evacuation disorder not only demonstrated that prucalopride in a dose of 2 and 4 mg accelerates overall colonic transit and ascending colonic emptying, but also gastric emptying and small bowel transit; the effect appeared to be dose dependent ([@b6-ce3_1p45]). The results of this mechanistic study in patients with idiopathic constipation further suggest the possible usefulness of prucalopride not only in patients with constipation but also in patients with an associated upper or generalized gastrointestinal motility disorder.

Tolerability and safety
=======================

Overall prucalopride in a dose of 1--4 mg once daily was well tolerated, with the frequency of adverse events tending to be dose dependent. Adverse events were mild or moderate in all reported phase II and phase III studies, and disappeared in most patients within the first week of treatment. They included headache and nausea, and, less frequently, an excessive gastrointestinal response with abdominal cramps, diarrhea, and flatulence ([@b31-ce3_1p45]; [@b39-ce3_1p45]; [@b30-ce3_1p45]; [@b16-ce3_1p45]; [@b63-ce3_1p45]).

Adverse events eventually resulted in discontinuation of prucalopride because of complaints that persisted after dose reduction. In the first phase II trial with the 4 mg regimen, adverse events were mild in two-thirds of the patients and resulted in discontinuation of the prokinetic drug in three out of 37 (8.1%) ([@b16-ce3_1p45]). In the subsequent phase II trial with the 1 mg regimen, three out of 37 (8.1%) prucalopride-treated patients withdrew from treatment because of adverse events ([@b30-ce3_1p45]). Overall, 77% of the prucaloprideand 60% of the placebo-treated patients reported one or more adverse events. The frequency of nausea, abdominal pain, and headache occurred at a similar frequency in both treatment groups, whilst diarrhea and flatulence were more common with prucalopride 1 mg once daily. Severe adverse events were reported in similar proportions (36% for prucalopride versus 34% for placebo).

In the dose-finding phase II study most adverse events were also mild or moderate in severity ([@b61-ce3_1p45]). Headache, the most frequent adverse event, was more frequently reported by patients receiving prucalopride. Three of the 16 patients (18.8%) in the 2 mg group withdrew from treatment because of adverse events, which were predominantly gastrointestinal in nature. In elderly patients prucalopride was generally well tolerated. The most common adverse events were abdominal pain, back pain, headache, nausea, and diarrhea, which also occurred in the placebo group. [@b41-ce3_1p45] reported moderate-to-severe adverse events in four out of 11 patients with constipation due to spinal cord injury receiving prucalopride 2 mg necessitating discontinuation of treatment in two patients (18.2%).

Clinically relevant changes in cardiovascular or laboratory parameters were reported in none of the patients treated with prucalopride. Also, the use of prucalopride for longer periods of time (up to 24 months) and in elderly patients did not result in clinically significant changes in laboratory values or vital signs, including cardiovascular parameters ([@b39-ce3_1p45]; [@b63-ce3_1p45]; [@b67-ce3_1p45]).

These data were recently confirmed by results of a large 12-week, multicenter, phase III trial conducted in the US ([@b9-ce3_1p45]). Nausea, vomiting, diarrhea, and headache were reported more frequently by patients receiving prucalopride 2 and 4 mg than those receiving placebo. However, these adverse events were mild or moderate in severity and occurred primarily during the first days of treatment. Transient serious adverse events were reported by only 1.4% and 3.4% of the patients receiving prucalopride 2 and 4 mg, respectively. Incidences of adverse cardiovascular effects were similar among the three treatment groups and there were no clinically relevant changes in the electrocardiographic variables including corrected QT (QTc F) interval.

Based on the available clinical experience prucalopride, a prokinetic with functional overlap with the 5-HT~4~ receptor agonists cisapride and tegaserod (both of which have been withdrawn from the market due to adverse cardiac events), appears safe. The drug was not associated with adverse ventricular repolarization effects or associated with increased ischemic events ([@b63-ce3_1p45]; [@b9-ce3_1p45]). Electrophysiologic studies with prucalopride on ion-channel currents in isolated cardiac cells showed that the drug had a lower affinity for the cardiac potassium HERG channel than does cisapride, a prokinetic that is associated with a risk of torsade de pointes arrhythmias due to excessive action potential prolongation through HERG-channel inhibition. These studies seem to indicate that although prucalopride blocks HERG channels, a large safety margin at therapeutic concentrations exists ([@b11-ce3_1p45]). Nevertheless, some safety concerns persist and additional data have been requested by some authors ([@b49-ce3_1p45]). Taking into account that at the present time relatively few patients have been exposed to prucalopride for longer periods of time, the low rate of occurrence of the life-threatening cardiac side effects related to prolongation of QTc and the lack of more complete electrophysiologic and pharmacologic data warrants a careful assessment of the long-term benefit-risk ratio when prescribing the drug in an individual patient with chronic constipation amenable to prokinetic drug treatment.

Economic evidence
=================

There are no published data on the assessment of resource utilization with prucalopride treatment or studies providing an economic evaluation of prucalopride in chronic functional constipation.

There appears to be less need for laxatives and thus less cost and adverse events that may interfere with the ability to work in patients successfully treated with prucalopride. However, there are as yet no studies that compare prucalopride and laxatives.

Dosage, administration, and formulations
========================================

Prucalopride is available in oral tablets of 0.5, 1, 2, and 4 mg. The performed trials provide valuable information on the frequency and timing of prucalopride dosing, but it is clear that their results may need to be adapted to the needs of individual patients. Once daily administration appears to be appropriate and this may be related to the long plasma elimination half-life of prucalopride of approximately 24 hours ([@b6-ce3_1p45]). The fast mode of action of the drug with a maximum concentration of ∼3 hours ([@b6-ce3_1p45]) opens up the possibility of intermittent treatment, but data are currently not available. The effect of prucalopride on stool frequency and constipation-related symptoms is clearly dose related. Prucalopride 2 mg once daily appears to be consistently equally as effective as 4 mg once daily in all published studies. The effect of 1 mg is less consistent and a dose regimen of 0.5 mg once daily proved suboptimal in all studies.

Place in therapy
================

Chronic constipation is a common motility disorder that may affect overall wellbeing and quality of life. A subgroup of patients with chronic constipation not only has a delayed colonic transit but also a disordered transit through the upper gastrointestinal tract, associated with symptoms of dyspepsia. Another subgroup has symptoms related to impaired rectal emptying due to pelvic floor dysfunction or rectoanal dyssynergia.

The majority of the currently available treatments for chronic constipation are relatively ineffective, particularly for more severe cases, and have not been tested in well-controlled modern trials. Laxatives remain the most popular treatment for chronic constipation although systematic reviews of these agents do not provide unequivocal evidence that they result in adequate relief of constipation. In daily practice they appear to be generally effective and safe, with no evidence of loss of effect with time in the majority of patients. Tolerance seems to occur mainly in patients with slow transit constipation in whom only stimulant laxatives are effective. A major limitation of chronic treatment with laxatives, however, is that although they increase stool frequency, they do not relieve all the constipation-associated symptoms such as bloating, abdominal discomfort, and pain, resulting in poor compliance. They also may induce troublesome adverse events including flatulence, bloating, and abdominal cramping pain, in itself often associated with chronic constipation.

Uncovering the role of 5-HT~4~ receptors in the gastrointestinal tract and the development of selective 5-HT~4~ receptor agonists that have clear-cut prokinetic activities offered great opportunities for the treatment of patients with different types of chronic constipation. Specific 5-HT agonists, in contrast to other available drugs that increase intestinal motor activity such as metoclopramide and prostigmine that are poorly tolerated, are an innovative and successful new approach to the treatment of constipation.

Prucalopride is a selective high-affinity 5-HT~4~ receptor agonist that was developed for constipation, and based on available evidence and compared with its predecessors, cisapride and tegaserod, offers improved efficacy and safety to treat patients with severe chronic constipation. This potent, highly selective 5-HT~4~ agonist proved an efficacious, safe, and well-tolerated treatment for the multiple symptoms of chronic constipation. Prucalopride has a rapid onset of enterokinetic activity and increases the number of complete spontaneous bowel movements. Adequate relief of constipation among patients with severe constipation occurs significantly more frequently in patients taking prucalopride compared with placebo. It normalizes bowel function in about 25% of treated patients and has a beneficial effect on associated symptoms such as hard stools, feeling of incomplete evacuation, and straining. Most importantly, it results in improved sense of general wellbeing and quality of life.

Prucalopride is well tolerated and remained effective in an RCT of up to 12 weeks' duration. The most common adverse events of nausea and headache occurred in the first week of treatment in the majority of patients. Prucalopride also appears to be a safe drug and there is no evidence at the present time that it affects the electrocardiogram or prolongs QTc interval.

A single daily dose appears appropriate. The effects on stool frequency, constipation-associated symptoms as well as adverse effects are dose related. Prucalopride 2 mg once daily appears to be as effective as 4 mg once daily in clinical trials. The effect of 1 mg is less consistent and a dose regimen of 0.5 mg once daily proved suboptimal. The percentages of responders to 2 and 4 mg appear similar. A 2 mg dose regimen appears optimal to start, with dose escalation when needed and dose reduction in the case of adverse events consistent with the prokinetic action that would preclude further treatment with 2 mg once daily.

Prucalopride significantly increases the stool frequency in a clinically significant percentage of patients, but the effect may remain suboptimal in patients with more severe constipation. Prokinetic agents can then be used in combination with other available therapeutic options such as stimulant laxatives, which were used as escape medication in the RCT, or reeducation of the pelvic floor. Taking into account the rapid action of prucalopride, one could also use this colokinetic agent intermittently and not on a daily basis, side effects permitting. Patients with chronic constipation associated with a disordered transit through the upper gut may also benefit from prucalopride as it accelerates not only total colonic transit and ascending colon emptying but also gastric emptying and small bowel transit. Patients with chronic constipation and pelvic floor disorders are traditionally excluded from trials with colokinetic agents to avoid potential error in the evaluation of the therapeutic potential of these agents in patients with chronic constipation that have no evidence of disordered rectal emptying. Taking into account the obvious overlap of different subtypes of constipation, one may speculate that prucalopride, by accelerating oro-cecal and segmental colonic transit and improving stool consistency, may also contribute to better symptom control in patients with constipation and rectal evacuation disturbances. This is in accordance with the reported beneficial effect of prucalopride in patients with paraplegia.

Professor Coremans received honoraria from Janssen Pharmaceutica between 1999 and 2002 for conducting trials with prucalopride. He served on advisory boards for Janssen Pharmaceutica until 2002.

###### 

Evidence base included in the review

                                                                 **Number of records**   
  -------------------------------------------------------------- ----------------------- ----
  Initial search                                                 73                      13
    records excluded                                             67                      4
    records included                                             6                       9
  Additional studies identified                                  0                       2
  Total records included                                         6                       11
  Level 1 clinical evidence (systematic review, meta analysis)   0                       0
  Level 2 clinical evidence (RCT)                                6                       11
  Economic evidence                                              0                       0

For definitions of levels of evidence, see inside back cover or *Core Evidence* website (<http://www.coremedicalpublishing.com>).

RCT, randomized controlled trial.
